Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引：0
|
作者：
Kasahara, K. [1 ]
Sone, T. [1 ]
Nishi, K. [2 ]
Shibata, K. [3 ]
Araya, T. [4 ]
Shirasaki, H. [5 ]
Yoneda, T. [6 ]
Kase, K. [7 ]
Nishikawa, S. [1 ]
Kimura, H. [1 ]
Tambo, Y. [1 ]
机构：
[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan
[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan
[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan
[7] Keiju Med Ctr, Resp Med, Nanao, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Pembrolizumab; 1st line treatment; PD-L1 high expression;
D O I：
10.1016/j.jtho.2019.08.953
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-50
引用
收藏
页码：S460 / S460
页数：1
相关论文
共 50 条
  • [21] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
  • [22] Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer
    Parmar, Ambica
    Lu, Brandon
    Luo, Jin
    Chan, Kelvin K.
    FUTURE ONCOLOGY, 2024,
  • [23] First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices
    Velcheti, V.
    Chandwani, S.
    Chen, X.
    Pietanza, M. C.
    Burke, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 18 - 18
  • [24] Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
    Wakuda, Kazushige
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Endo, Masahiro
    Gon, Yasuhiro
    Takahashi, Toshiaki
    LUNG CANCER, 2021, 151 : 60 - 68
  • [25] PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
    Miyawaki, Eriko
    Murakami, Haruyasu
    Mori, Keita
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (05) : 617 - 622
  • [26] Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression
    McKay, C.
    Cheng, J.
    Yip, P. Y.
    Tognela, A.
    Bray, V. J.
    Kok, P. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1575 - S1575
  • [27] Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer
    Zhou, Zi-Chao
    Chen, Kai-Yan
    Li, Na
    Xie, Ming-Ying
    Sheng, Jia-Min
    Fan, Yun
    Huang, Zhi-Yu
    THORACIC CANCER, 2022, 13 (16) : 2291 - 2300
  • [28] PD-L1 expression in different samples of non-small cell lung cancer
    Kovacevic, M.
    Kern, I.
    VIRCHOWS ARCHIV, 2017, 471 : S104 - S104
  • [29] PD-L1 expression: An emerging biomarker in non-small cell lung cancer
    Adam, Julien
    Planchard, David
    Marabelle, Aurelien
    Soria, Jean-Charles
    Scoazec, Jean-Yves
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2016, 36 (01) : 94 - 102
  • [30] PD-L1 Expression and Molecular Alterations in Non-Small Cell Lung Cancer
    Ebare, K.
    Song, W.
    Opitz, L.
    Rosca, O.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (03): : S52 - S53
12345